GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » Float Percentage Of Total Shares Outstanding

Albireo Pharma (FRA:BDQM) Float Percentage Of Total Shares Outstanding : 76.61% (As of Jun. 09, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Albireo Pharma Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Albireo Pharma's float shares is 15.89 Mil. Albireo Pharma's total shares outstanding is 20.74 Mil. Albireo Pharma's float percentage of total shares outstanding is 76.61%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Albireo Pharma's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Albireo Pharma's Institutional Ownership is 46.76%.

Albireo Pharma Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Albireo Pharma's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding=Float Shares/Total Shares Outstanding
=15.89/20.74
=76.61%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Albireo Pharma (FRA:BDQM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albireo Pharma Inc (FRA:BDQM) » Definitions » Float Percentage Of Total Shares Outstanding
Comparable Companies
IGMS KNSA ALLO RGNX COGT QURE MRUS VKTX ARQT RAPT OCSE:NOVO B ASX:CSL REGN VRTX MRNA XKRX:207940 BNTX SGEN HKSE:02269 OCSE:GMAB
Traded in Other Exchanges
N/A
Address
53 State Street, 19th Floor, Boston, MA, USA, 02109
Website
https://www.albireopharma.com
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.

Albireo Pharma (FRA:BDQM) Headlines

No Headlines